Search results for "DUCTAL ADENOCARCINOMA"

showing 10 items of 40 documents

Development of natural and synthetic compounds as kinase inhibitors targeting cancer cells and cancer stem cells

2023

Pancreatic ductal adenocarcinomaInhibition of migrationantibiotic resistanceImidazo[21-b][134]thiadiazole derivativeskinase inhibitorsanti-biofilm agentsAntiproliferative activityFAK inhibitionSettore CHIM/08 - Chimica Farmaceutica
researchProduct

Molecular Characterization of a Long Term Survivor Double Metastatic Non Small Sell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gef…

2019

Management of multiple primary cancers, a not so infrequent event in oncology practice, is a critical issue due to the lack of literature . In this study, we reported the case of a patient with metachronous double metastatic non small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) who received gefitinib in combination with gemcitabine plus nab-paclitaxel and with mFOLFOX6 in first and second line, respectively. She achieved a progression free survival and an overall survival (OS) of 28 months for NSCLC and PFS-1 and OS of 20 and 13 months, respectively for PDAC. Moreover, the combination of gefitinib and chemotherapies treatments displayed a good safety profile. Given …

Second-line therapyChemotherapyPancreatic ductal adenocarcinomabusiness.industrymedicine.medical_treatmentLong Term Survivormedicine.diseaseGemcitabineGefitinibCancer researchmedicineLung cancerbusinessoncology_oncogenicsmedicine.drugNab-paclitaxel
researchProduct

Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Itali…

2022

Constitutional BRCA1/BRCA2 pathogenic or likely pathogenic variants (PVs) are associated with an increased risk for developing breast and ovarian cancers. Current evidence indicates that BRCA1/2 PVs are also associated with pancreatic cancer, and that BRCA2 PVs are associated with prostate cancer risk. The identification of carriers of constitutional PVs in the BRCA1/2 genes allows the implementation of individual and family prevention pathways, through validated screening programs and risk-reducing strategies. According to the relevant and increasing therapeutic predictive implications, the inclusion of BRCA testing in the routine management of patients with breast, ovarian, pancreatic and…

Societies ScientificMaleOvarian NeoplasmsCancer Researchgenetic counselingBRCABRCA testing; BRCA-related cancer; BRCA1; BRCA2; PARP inhibitors; genetic counseling; pancreatic ductal adenocarcinomaProstatic Neoplasmspancreatic ductal adenocarcinomaScientificSettore MED/03 - GENETICA MEDICABRCA testing; BRCA-related cancer; BRCA1; BRCA2; PARP inhibitors; genetic counseling; pancreatic ductal adenocarcinoma; Female; Humans; Italy; Male; Societies Scientific; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic NeoplasmsBRCA1BRCA2BRCA-related cancerPancreatic NeoplasmsBRCA testingPARP inhibitorOncologyItalyHumansFemaleSocietiesPARP inhibitors
researchProduct

Malignant epithelial/exocrine tumors of the pancreas

2020

Summary Pancreatic malignant exocrine tumors represent the most important cause of cancer-related death for pancreatic neoplasms. The most common tumor type in this category is represented by pancreatic ductal adenocarcinoma (PDAC), an ill defined, stroma-rich, scirrhous neoplasm with glandular differentiation. Here we present the relevant characteristics of the most important PDAC variants, namely adenosquamous carcinoma, colloid carcinoma, undifferentiated carcinoma, undifferentiated carcinoma with osteoclast-like giant cells, signet ring carcinoma, medullary carcinoma and hepatoid carcinoma. The other categories of malignant exocrine tumors, characterized by fleshy, stroma-poor, circumsc…

acinarPathologymedicine.medical_specialtyAdenosquamous carcinomapancreatic cancerPancreatoblastomapancreatic ductal adenocarcinomaReviewAdenocarcinomaGlandular DifferentiationPathology and Forensic MedicinePancreatic cancersolid pseudopapillary.medicineCarcinomaNeoplasmHumansacinar; pancreatic cancer; pancreatic ductal adenocarcinoma; PDAC; solid pseudopapillaryPancreasbusiness.industryPDACPDAC; acinar; pancreatic cancer; pancreatic ductal adenocarcinoma; solid pseudopapillarymedicine.diseasePancreas ExocrinePancreatic Neoplasmssolid pseudopapillarymedicine.anatomical_structureMedullary carcinomaPancreasbusinessCarcinoma Pancreatic Ductal
researchProduct

3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma

2020

A new series of imidazo[2,1-b][1,3,4]thiadiazole derivatives was efficiently synthesized and screened for their in vitro antiproliferative activity on a panel of pancreatic ductal adenocarcinoma (PDAC) cells, including SUIT-2, Capan-1 and Panc-1. Compounds 9c and 9l, showed relevant in vitro antiproliferative activity on all three pre-clinical models with half maximal inhibitory concentration (IC50) ranging from 5.11 to 10.8 &micro

antiproliferative activityPancreatic ductal adenocarcinomaendocrine system diseasespancreatic cancerPharmaceutical ScienceImidazo[21-b][134]thiadiazole derivativeAnalytical Chemistryresistancelcsh:QD241-44103 medical and health sciences0302 clinical medicinelcsh:Organic chemistryPancreatic cancerDrug DiscoverymedicinePhysical and Theoretical ChemistryIC50imidazo[21-<i>b</i>][134]thiadiazole derivatives030304 developmental biologyIndole test0303 health sciencesmigration assayMigration AssayChemistryOrganic ChemistryBiological activityindole compoundsmedicine.diseaseIn vitrodigestive system diseasesIndole compoundChemistry (miscellaneous)Cell culture030220 oncology & carcinogenesisCancer researchMolecular Medicine
researchProduct

Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole derivatives: as anticancer and antibiofilm agents, and preclinical invest…

2020

antiproliferative activityStaphylococcal biofilm inhibitorhypoxiaAnti-virulence agentpancreatic ductal adenocarcinomachemoresistancemodulation of EMTlactate dehydrogenaseproton-coupled folate transporterspheroids shrinkageSettore CHIM/08 - Chimica Farmaceuticamalignant pleural and peritoneal mesotheliomaanti-biofilm agentimidazo[21-b][134]thiadiazole derivativeinhibition of migrationPTK2/FAKxenograftpemetrexedprognosi
researchProduct

Appleby Procedure (Distal Pancreatectomy With Celiac Artery Resection) for Locally Advanced Pancreatic Carcinoma: Indications, Outcomes, and Imaging

2019

OBJECTIVE. We describe the indications, surgical technique, outcome, and imaging findings in patients with pancreatic ductal adenocarcinoma (PDAC) treated with distal pancreatectomy and celiac artery resection (modified Appleby procedure). CONCLUSION. Distal pancreatectomy and celiac artery resection is a feasible surgery in selected patients with locally advanced PDAC. Knowledge of surgical technique and imaging features may aid radiologists in identifying patients with locally invasive PDAC who might benefit from resection and identifying characteristic distal pancreatectomy and celiac artery resection complications.

medicine.medical_specialtyPancreatic ductal adenocarcinomaendocrine system diseasesbusiness.industryLocally advancedGeneral Medicinedigestive system diseases030218 nuclear medicine & medical imagingResectionsurgery03 medical and health sciences0302 clinical medicineCeliac artery030220 oncology & carcinogenesismedicine.arterypancreatic adenocarcinomamedicineRadiology Nuclear Medicine and imagingIn patientPancreatic carcinomaRadiologySettore MED/36 - Diagnostica Per Immagini E RadioterapiaDistal pancreatectomybusinessCTAmerican Journal of Roentgenology
researchProduct

Structural Manipulations of Marine Natural Products Inspire a New Library of 3-Amino-1,2,4-Triazine PDK Inhibitors Endowed with Antitumor Activity in…

2023

Pancreatic ductal adenocarcinoma (PDAC) is one of the main aggressive types of cancer, characterized by late prognosis and drug resistance. Among the main factors sustaining PDAC progression, the alteration of cell metabolism has emerged to have a key role in PDAC cell proliferation, invasion, and resistance to standard chemotherapeutic agents. Taking into account all these factors and the urgency in evaluating novel options to treat PDAC, in the present work we reported the synthesis of a new series of indolyl-7-azaindolyl triazine compounds inspired by marine bis-indolyl alkaloids. We first assessed the ability of the new triazine compounds to inhibit the enzymatic activity of pyruvate de…

nortopsentin analoguespancreatic ductal adenocarcinoma (PDAC); nortopsentin analogues; antitumor activity; pyruvate dehydrogenase kinases (PDKs); cytotoxic activity; metabolic alterations; ligand-based homology modeling; KRASDrug Discoveryligand-based homology modelingKRASPharmaceutical Scienceantitumor activitymetabolic alterationspancreatic ductal adenocarcinoma (PDAC)Pharmacology Toxicology and Pharmaceutics (miscellaneous)cytotoxic activitypyruvate dehydrogenase kinases (PDKs)
researchProduct

Targeting PAM signaling pathway in the treatment of pancreatic ductal adenocarcinoma

pancreatic ductal adenocarcinoma PAM
researchProduct

DESIGN OF SF3B1 SUBUNIT MODULATORS OF THE SF3B SPLICEOSOME COMPLEX

2022

The subject of this dissertation is the search for new therapeutic strategies for pancreatic cancer and aims to implement a Drug Discovery process for the rational design and synthesis of molecules active in the modulation of pathways related to the regulation of pre-mRNA splicing process. This research project is the result of a joint PhD between the University of Palermo, Italy, and the Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands. It integrates complementary skills in pharmaceutical chemistry and translational cancer research with a special focus on the rational design of new anticancer compounds potentially active on SF3B1 (Splicing Factor 3B …

splicing4]thiadiazole compoundsdrug resistancehuman equilibrative nucleoside transporter-13mesotheliomaSF3B1gemcitabinepancreatic ductal adenocarcinoma1-b][1SF3B1 splicing imidazo[21-b][134]thiadiazole compounds pancreatic ductal adenocarcinoma gemcitabine human equilibrative nucleoside transporter-1 drug resistance mesotheliomaimidazo[2
researchProduct